Glucagon-like peptide-1 receptor agonists : A new step towards weight management: Review Article

Mohamed Omar

doi:10.58372/2835-6276.1073

Authors

Mohamed Omar

DOI:

https://doi.org/10.58372/2835-6276.1073

Keywords:

Diabetic, Obesity, Glucagon-like peptide-1 receptor agonist , GLP-1-RA

Abstract

Obesity, a widely established chronic disease, presents challenges in its treatment. Unfortunately, obesity is often accompanied with a multitude of chronic maladies that substantially elevate health risks. Thus, it is critical to promote weight management in order to hinder the development of severe complications and to improve the overall patient well-being. Several approaches exist to address this condition and induce weight loss. In addition to lifestyle adjustments by physical activity and dietary modifications, some emerging medications could provide promising results in achieving a reduction in weight.

This report discusses the potential implementation of Glucagon-like peptide-1 receptor agonist (GLP-1-RA) as a therapeutic option for obesity. Specifically, it will examine the efficacy of GLP-1-RA in the promotion of weight loss in both diabetic and non-diabetic patients. Nevertheless, it is essential to highlight the potential side effects associated with the use of this drug.

References

Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med (2017) 377(1):13–27. doi: 10.1056/NEJMoa1614362

Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med (2017) 376(15):1492. doi: 10.1056/NEJMc1701944

Borrelli S, Garofalo C, Mallamaci F, Tripepi G, Stanzione G, Provenzano M, et al. Short-term blood pressure variability in nondialysis chronic kidney disease patients: correlates and prognostic role on the progression of renal disease. J Hypertens (2018) 36 (12):2398–405. doi: 10.1097/HJH.0000000000001825

Mallamaci F, Tripepi G, D'Arrigo G, Borrelli S, Garofalo C, Stanzione G, et al. Blood pressure variability, mortality, and cardiovascular outcomes in CKD patients. Clin J Am Soc Nephrol.: CJASN (2019) 14(2):233–40. doi: 10.2215/CJN.04030318

Pratama KG, Tandarto K, Hengky A. Weight loss effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with obesity without diabetes: A systematic review. Acta Endocrinol (Buchar). (2022) 18(2):216–24. doi: 10.4183/ aeb.2022.216

Pelle MC, Provenzano M, Zaffina I, Pujia R, Giofrè F, Lucà S, et al. Role of a dual glucose-dependent insulinotropic peptide (GIP)/Glucagon-like peptide-1 receptor agonist (Twincretin) in glycemic control: From pathophysiology to treatment. Life (Basel). (2021) 12(1):29. doi: 10.3390/life12010029

Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, et al. European Guidelines for obesity management in adults [published correction appears in obes facts. Obes Facts. (2015) 8(6):402–24. doi: 10.1159/000442721

Luniewski, M., Matyjaszek-Matuszek, B., & Lenart-Lipińska, M. (2023). Diagnosis and non-invasive treatment of obesity in adults with type 2 diabetes mellitus: A review of guidelines. Journal of Clinical Medicine, 12(13), 4431. doi:https://doi.org/10.3390/jcm12134431

Matyjaszek-Matuszek, B.; Szafraniec, A.; Porada, D. Pharmacotherapy of obesity—State of the art. Endokrynol. Pol. 2018, 69, 448–457. [CrossRef]

Thrasher, J. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. Am. J. Med. 2017, 130, S4–S17. [CrossRef]

Pi-Sunyer, X.; Astrup, A.; Fujioka, K.; Greenway, F.; Halpern, A.; Krempf, M.; Lau, D.C.W.; le Roux, C.W.; Violante Ortiz, R.; Jensen, C.B.; et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N. Engl. J. Med. 2015, 373, 11–22. [CrossRef] [PubMed]

Pedersen, S.; Manjoo, P.; Wharton, S. Canadian Adult Obesity Clinical Practice Guidelines: Pharmacotherapy in Obesity Management. Available online: https://obesitycanada.ca/guidelines/pharmacotherapy

Pratley, R.E.; Aroda, V.R.; Lingvay, I.; Lüdemann, J.; Andreassen, C.; Navarria, A.; Viljoen, A. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): A randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018, 6, 275–286. [CrossRef] [PubMed]

Htike, Z.Z.; Zaccardi, F.; Papamargaritis, D.; Webb, D.R.; Khunti, K.; Davies, M.J. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes. Metab. 2017, 19, 524–536. [CrossRef] [PubMed]

Frias, J.P.; Wynne, A.G.; Matyjaszek-Matuszek, B.; Bartaskova, D.; Cox, D.A.; Woodward, B.; Li, Y.G.; Tham, L.S.; Milicevic, Z. Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin. Diabetes Obes. Metab. 2019, 21, 2048–2057. [CrossRef]

Marso, S.P.; Bain, S.C.; Consoli, A.; Eliaschewitz, F.G.; Jódar, E.; Leiter, L.A.; Lingvay, I.; Rosenstock, J.; Seufert, J.; Warren, M.L.; et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N. Engl. J. Med. 2016, 375, 1834–1844. [CrossRef]

Marso, S.P.; Daniels, G.; Brown-Frandsen, K. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2016, 375, 311–322. [CrossRef]

Gerstein, H.C.; Colhoun, H.M.; Dagenais, G.R.; Diaz, R.; Lakshmanan, M.; Pais, P.; Probstfield, J.; Riesmeyer, J.S.; Riddle, M.C.; Rydén, L.; et al. Dulaglutide and cardiovascular outcomes in Type 2 diabetes (REWIND): A double-blind, randomised placebocontrolled trial. Lancet 2019, 394, 121–130. [CrossRef]

Care, D.; Suppl, S.S. Obesity management for the treatment of type 2 diabetes: Standards of medical care in diabetes—2020. Diabetes Care 2020, 43 (Suppl. S1), S89–S97. [CrossRef]

American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes—2020. Diabetes Care 2020, 43 (Suppl. S1), S98–S110. [CrossRef]

Matuszek, B.; Szafraniec, A.; Porada, D. Pharmacotherapy of obesity—State of the art. Endokrynol. Pol. 2018, 69, 448–457. [CrossRef]

Astrup, A.; Rössner, S.; Van Gaal, L.; Rissanen, A.; Niskanen, L.; Al Hakim, M.; Madsen, J.; Rasmussen, M.F.; Lean, M.E.; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet 2009, 374, 1606–1616. [CrossRef] [PubMed]

Kanwal, S.; AlEmadi, E.A. Liraglutide for Weight Management, Critical Analysis of Efficacy and Side effects in Nondiabetic, individuals with obesity: A Comprehensive Systematic Review. Middle East J. Fam. Med. 2021, 19, 72–83.

Field, B.C.T.; Wren, A.M.; Cooke, D.; Bloom, S.R. Gut Hormones as Potential New Targets for Appetite Regulation and the Treatment of Obesity. Drugs 2008, 68, 147–163. [CrossRef]

Zander, M.; Madsbad, S.; Madsen, J.L.; Holst, J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: A parallel-group study. Lancet 2002, 359, 824–830. [CrossRef]

Garber, A.J. Incretin-based therapies in the management of type 2 diabetes: Rationale and reality in a managed care setting. Am. J. Manag. Care 2010, 16 (Suppl. S7), S187–S194. [PubMed]

Isidro, M.L.; Cordido, F. Drug treatment of obesity: Established and emerging therapies. Mini-Rev. Med. Chem. 2009, 9, 664–673. [CrossRef] [PubMed]

Matyjaszek-Matuszek, B.; Szafraniec, A.; Porada, D. Pharmacotherapy of obesity—State of the art. Endokrynol. Pol.; 2018; 69, pp. 448-457. [DOI: https://dx.doi.org/10.5603/EP.2018.0048]

FDA. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weightmanagement-first-2014

Storgaard, H.; Cold, F.; Gluud, L.L.; Vilsbøll, T.; Knop, F.K. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes. Metab.; 2017; 19, pp. 906-908. [DOI: https://dx.doi.org/10.1111/dom.12885]

Monami, M.; Nreu, B.; Scatena, A.; Cresci, B. Safety issues with glucagon-like peptide-1 receptor agonists: Pancreatitis, pancreatic cancer, and cholelithiasis. Data from randomised controlled trials. Diabetes Obes. Metab.; 2017; 19, pp. 1233-1241. [DOI: https://dx.doi.org/10.1111/dom.12926]

Knudsen, L.B.; Madsen, L.W.; Andersen, S.; Almholt, K.; De Boer, A.S.; Drucker, D.J.; Gotfredsen, C.; Egerod, F.L.; Hegelund, A.C.; Jacobsen, H. et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology; 2010; 151, pp. 1473-1486. [DOI: https://dx.doi.org/10.1210/en.2009-1272]

Bezin, J.; Gouverneur, A.; Pénichon, M.; Mathieu, C.; Garrel, R.; Hillaire-Buys, D.; Pariente, A.; Faillie, J.-L. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care; 2022; 46, pp. 384-390. [DOI: https://dx.doi.org/10.2337/dc22-1148]

C.A.; Stüurmer, T. Putting GLP-1 RAs and Thyroid Cancer in Context: Additional Evidence and Remaining Doubts. Diabetes Care; 2023; 46, pp. 249-251. [DOI: https://dx.doi.org/10.2337/dci22-0052]

Chiu, W.Y.; Shih, S.R.; Tseng, C.H. A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer. Exp. Diabetes Res.; 2012; 2012, 924168. [DOI: https://dx.doi.org/10.1155/2012/924168] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22693487]

EMA (European Medicines Agency). Saxenda: EPAR—Product Information. 2022; Available online: https://www.ema.europa.eu/documents/product-information/saxenda-epar-product-information_en.pdf (accessed on 15 June 2023).

EMA (European Medicines Agency). Wegovy: EPAR—Product Information. 2023; Available online: https://www.ema.europa.eu/documents/overview/wegovy-epar-medicine-overview_en.pdf (accessed on 15 June 2023).

Gallwitz B. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update). Drugs Today (Barc). 2007 Nov;43(11):801-14. doi: 10.1358/dot.2007.43.11.1157620. PMID: 18174966. https://pubmed.ncbi.nlm.nih.gov/18174966.